HC Wainwright & Co. Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $16

Benzinga Newsdesk www.benzinga.com Neutral 54.4%

Neg 0% Neu 54.4% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $16.